FDA Recalls NORepinephrine Injection Due to Sterility Concerns
Central Admixture Pharmacy Services recalled 6,414 bags of NORepinephrine injection nationwide after an FDA inspection questioned the sterility of the product. Healthcare facilities should stop using and quarantine affected lots.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is a sterile injectable pharmaceutical product where FDA inspection found lack of sterility assurance. Per the rubric, risk-of-harm products where injury has not yet been reported receive a score of 3. No illnesses or deaths have been reported.
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling 6,414 bags of NORepinephrine added to 0.9% sodium chloride injection (32 mcg/mL, 250 mL bags) nationwide. The recall was initiated after an FDA inspection raised concerns about the sterility of products marketed as sterile.
The affected product is NDC 71285-8096-1 from the manufacturer's Allentown, Pennsylvania facility. Multiple lot numbers with expiration dates from April 2023 through July 2023 are included in the recall.
Healthcare providers and facilities should immediately stop using any affected lots and quarantine remaining inventory. Consult the FDA or the manufacturer for guidance on affected products and any steps needed to address previously administered doses.
The recalled product
- Product
- NORepinephrine added to 0.9% sodium chloride, 8 mg/250 mL* (32 mcg/mL), 250 mL per bag, Rx only, Central Admixture Pharmacy Services, Inc., 6580 Snowdrift Rd., Ste 100, Allentown, PA 18106, NDC 71285-8096-1.
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Category
- Drug — Injectable
- Hazard
- sterility-failure
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot # 37-882989
- Exp 04/28/2023
- 37-883827
- 37-883829
- 37-883830
- 37-883833
- 37-883858
- Exp 05/02/2023
- 37-884758
- Exp 05/05/2023
- 37-885357
- Exp 05/08/2023
- 37-885748
- 37-885751
- Exp 05/09/2023
- 37-887409
- 37-887410
- Exp 05/16/2023
- 37-888863
- 37-888867
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27